文献速递临床试验与 GCP基础与转化研究

IMI2-PainCare-BioPain-RCT1:在健康受试者中研究拉考沙胺、普瑞巴林和曲马多对周围神经兴奋性测试所观察到的疼痛处理生物标志物影响的随机双盲安慰剂对照交叉多中心试验方案

IMI2-PainCare-BioPain-RCT1: study protocol for a randomized, double-blind, placebo-controlled, crossover, multi-center trial in healthy subjects to investigate the effects of lacosamide, pregabalin, and tapentadol on biomarkers of pain processing observed by peripheral nerve excitability testing (NET).
PubMed 文献 · Trials · 2022-02-19

该方案描述一项在健康受试者中开展的多中心、单剂量、受试者与评估者盲、随机、安慰剂对照、4周期4序列交叉的药效学与药代动力学研究,比较拉考沙胺、普瑞巴林、曲马多和安慰剂单次口服后对神经兴奋性测试(NET)衍生生物标志物的影响。主要结局为比较大纤维感觉神经与运动神经的强度-持续时间时间常数(SDTC)在拉考沙胺与安慰剂间的差异。作者假设NET可作为未来1期临床试验中镇痛药靶点结合的生物标志物。

要点

  • 研究采用4周期4序列交叉设计,健康受试者单次口服拉考沙胺、普瑞巴林、曲马多或安慰剂,间隔至少1周。
  • 主要终点为拉考沙胺与安慰剂比较大纤维感觉神经和运动神经的SDTC。
  • 关键次要终点为小纤维感觉神经的SDTC;NET阈值追踪方案对刺激部位膜电位敏感。

核心结论

  • IMI2-PainCare-BioPain-RCT1假设NET可作为未来1期临床试验中镇痛药在伤害性系统该部位靶点结合的生物标志物,2期和3期临床试验也可能受益于这些工具进行患者分层。

研究设计与样本

  • 多中心、单剂量、受试者与评估者盲、随机、安慰剂对照、4周期4序列交叉的药效学与药代动力学研究,在健康受试者中开展。
  • 三种已知作用于伤害性系统的药物(拉考沙胺、普瑞巴林、曲马多)与安慰剂以单次口服剂量给药,间隔至少1周。
  • 在大纤维感觉和运动纤维以及小纤维感觉纤维中,于给药前和给药后三次获取NET衍生的生物标志物。
  • 运动与感觉NET在右侧腕部非致敏正常条件下评估,感知阈值追踪在双侧前臂皮肤非致敏和致敏条件下进行。
  • 采用序贯拒绝多重检验方法,主要分析总体α错误分配于两个主要结局:大纤维感觉神经的SDTC和大纤维运动神经的SDTC,比较拉考沙胺与安慰剂。

主要发现

  • 关键次要终点为小纤维感觉神经中测量的SDTC。
  • 其余治疗臂对关键NET结局的影响及药代动力学建模为预设的次要或探索性分析。
  • 皮肤高频电刺激用于诱导痛觉过敏;采集血样用于药代动力学目的,并收集疼痛评分及预测性心理特征。

关键数值与推荐

  • 主要结局:大纤维感觉神经的SDTC和大纤维运动神经的SDTC,比较拉考沙胺与安慰剂。
  • 关键次要终点:小纤维感觉神经中测量的SDTC。
  • 采用序贯拒绝多重检验方法,主要分析总体α错误分配于两个主要结局。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Few new drugs have been developed for chronic pain. Drug development is challenged by uncertainty about whether the drug engages the human target sufficiently to have a meaningful pharmacodynamic effect. IMI2-PainCare-BioPain-RCT1 is one of four similarly designed studies that aim to link different functional biomarkers of drug effects on the nociceptive system that could serve to accelerate the future development of analgesics. This study focusses on biomarkers derived from nerve excitability testing (NET) using threshold tracking of the peripheral nervous system. METHODS: This is a multisite single-dose, subject and assessor-blind, randomized, placebo-controlled, 4-period, 4-way crossover, pharmacodynamic (PD), and pharmacokinetic (PK) study in healthy subjects. Biomarkers derived from NET of large sensory and motor fibers and small sensory fibers using perception threshold tracking will be obtained before and three times after administration of three medications known to act on the nociceptive system (lacosamide, pregabalin, tapentadol) and placebo, given as a single oral dose with at least 1 week apart. Motor and sensory NET will be assessed on the right wrist in a non-sensitized normal condition while perception threshold tracking will be performed bilaterally on both non-sensitized and sensitized forearm skin. Cutaneous high-frequency electrical stimulation is used to induce hyperalgesia. Blood samples will be taken for pharmacokinetic purposes and pain ratings as well as predictive psychological traits will be collected. A sequentially rejective multiple testing approach will be used with overall alpha error of the primary analysis split across the two primary outcomes: strength-duration time constant (SDTC; a measure of passive membrane properties and nodal persistent Na+ conductance) of large sensory fibers and SDTC of large motor fibers comparing lacosamide and placebo. The key secondary endpoint is the SDTC measured in small sensory fibers. Remaining treatment arm effects on key NET outcomes and PK modelling are other prespecified secondary or exploratory analyses. DISCUSSION: Measurements of NET using threshold tracking protocols are sensitive to membrane potential at the site of stimulation. Sets of useful indices of axonal excitability collectively may provide insights into the mechanisms responsible for membrane polarization, ion channel function, and activity of ionic pumps during the process of impulse conduction. IMI2-PainCare-BioPain-RCT1 hypothesizes that NET can serve as biomarkers of target engagement of analgesic drugs in this compartment of the nociceptive system for future Phase 1 clinical trials. Phase 2 and 3 clinical trials could also benefit from these tools for patient stratification. TRIAL REGISTRATION: This trial was registered 25/06/2019 in EudraCT ( 2019-000942-36 ).

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Nochi Z, Pia H, Bloms-Funke P, et al. IMI2-PainCare-BioPain-RCT1: study protocol for a randomized, double-blind, placebo-controlled, crossover, multi-center trial in healthy subjects to investigate the effects of lacosamide, pregabalin, and tapentadol on biomarkers of pain processing observed by peripheral nerve excitability testing (NET). Trials. 2022. PMID: 35183242. doi:10.1186/s13063-022-06087-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。